Chinese General Practice ›› 2024, Vol. 27 ›› Issue (19): 2364-2374.DOI: 10.12114/j.issn.1007-9572.2023.0472
• Article • Previous Articles Next Articles
Received:
2023-06-14
Revised:
2024-02-26
Published:
2024-07-05
Online:
2024-04-28
Contact:
ZHU Hong
通讯作者:
朱宏
作者简介:
作者贡献:
黄书玮参与文章构思与设计、数据收集与管理、论文写作;周志衡、冯天元、刘莉参与文章构思与设计、数据收集与管理、论文修订;邓光璞、李尧天参与文章构思与设计、统计分析、审查和论文写作;朱宏负责文章构思与设计、文章的质量控制及审校,对文章整体负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0472
序号 | 公式 |
---|---|
式(1) | BMI=体质量/身高2 |
式(2) | TyG指数=ln[TG×FBG/2] |
式(3) | TyG-BMI指数=TyG指数×BMI |
式(4) | TyG-WC指数=TyG指数×WC |
式(5) | TG/HDL-C指数=TG/HDL-C |
式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
Table 1 Indicator calculation formula
序号 | 公式 |
---|---|
式(1) | BMI=体质量/身高2 |
式(2) | TyG指数=ln[TG×FBG/2] |
式(3) | TyG-BMI指数=TyG指数×BMI |
式(4) | TyG-WC指数=TyG指数×WC |
式(5) | TG/HDL-C指数=TG/HDL-C |
式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
---|---|---|---|---|---|---|---|
男 | 女 | 否 | 是 | 否 | 是 | ||
NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
χ2值 | 35.177 | 22.136 | 3.403 | ||||
P值 | <0.001 | <0.001 | 0.065 | ||||
组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
否 | 是 | 否 | 是 | ||||
NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 2 Comparison of general information and clinical data between HUA group and NHUA group
组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
---|---|---|---|---|---|---|---|
男 | 女 | 否 | 是 | 否 | 是 | ||
NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
χ2值 | 35.177 | 22.136 | 3.403 | ||||
P值 | <0.001 | <0.001 | 0.065 | ||||
组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
否 | 是 | 否 | 是 | ||||
NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
---|---|---|---|---|---|
性别(以男性为对照) | |||||
女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
吸烟(以不吸烟为对照) | |||||
吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
饮酒(以不喝酒为对照) | |||||
喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
运动(以不锻炼为对照) | |||||
锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
高血压(以非高血压为对照) | |||||
高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
Table 3 Univariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
---|---|---|---|---|---|
性别(以男性为对照) | |||||
女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
吸烟(以不吸烟为对照) | |||||
吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
饮酒(以不喝酒为对照) | |||||
喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
运动(以不锻炼为对照) | |||||
锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
高血压(以非高血压为对照) | |||||
高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
变量 | 模型4 | 模型5 | 模型6 | |||
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
METS-IR指数 | 1.170(1.142~1.200) | <0.001 |
Table 4 Multivariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
变量 | 模型4 | 模型5 | 模型6 | |||
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
METS-IR指数 | 1.170(1.142~1.200) | <0.001 |
变量 | OR(95%CI) | P值 | |
---|---|---|---|
TyG指数 | Q1 | ||
Q2 | 1.543(0.937~2.149) | <0.084 | |
Q3 | 2.487(1.628~3.346) | <0.001 | |
Q4 | 3.941(2.286~5.435) | <0.001 | |
TyG-BMI指数 | Q1 | ||
Q2 | 2.252(1.420~3.572) | 0.001 | |
Q3 | 2.949(1.883~4.617) | <0.001 | |
Q4 | 4.735(3.035~7.389) | <0.001 | |
TyG-WC指数 | Q1 | ||
Q2 | 2.955(2.201~3.709) | <0.001 | |
Q3 | 3.509(2.462~4.556) | <0.001 | |
Q4 | 5.184(3.850~6.518) | <0.001 | |
TG/HDL-C指数 | Q1 | ||
Q2 | 1.034(0.726~1.342) | 0.297 | |
Q3 | 2.863(2.023~3.703) | <0.001 | |
Q4 | 3.554(2.421~4.687) | <0.001 | |
Non HDL-C/HDL-C指数 | Q1 | ||
Q2 | 1.443(0.720~2.889) | 0.301 | |
Q3 | 2.551(1.482~4.390) | <0.001 | |
Q4 | 4.375(2.337~8.192) | <0.001 | |
METS-IR指数 | Q1 | ||
Q2 | 2.568(1.526~4.322) | <0.001 | |
Q3 | 3.473(2.097~5.752) | <0.001 | |
Q4 | 4.725(2.453~6.997) | <0.001 |
Table 5 Multivariate Logistic regression analysis of 6 insulin resistance replacement indexes for the occurrence of HUA
变量 | OR(95%CI) | P值 | |
---|---|---|---|
TyG指数 | Q1 | ||
Q2 | 1.543(0.937~2.149) | <0.084 | |
Q3 | 2.487(1.628~3.346) | <0.001 | |
Q4 | 3.941(2.286~5.435) | <0.001 | |
TyG-BMI指数 | Q1 | ||
Q2 | 2.252(1.420~3.572) | 0.001 | |
Q3 | 2.949(1.883~4.617) | <0.001 | |
Q4 | 4.735(3.035~7.389) | <0.001 | |
TyG-WC指数 | Q1 | ||
Q2 | 2.955(2.201~3.709) | <0.001 | |
Q3 | 3.509(2.462~4.556) | <0.001 | |
Q4 | 5.184(3.850~6.518) | <0.001 | |
TG/HDL-C指数 | Q1 | ||
Q2 | 1.034(0.726~1.342) | 0.297 | |
Q3 | 2.863(2.023~3.703) | <0.001 | |
Q4 | 3.554(2.421~4.687) | <0.001 | |
Non HDL-C/HDL-C指数 | Q1 | ||
Q2 | 1.443(0.720~2.889) | 0.301 | |
Q3 | 2.551(1.482~4.390) | <0.001 | |
Q4 | 4.375(2.337~8.192) | <0.001 | |
METS-IR指数 | Q1 | ||
Q2 | 2.568(1.526~4.322) | <0.001 | |
Q3 | 3.473(2.097~5.752) | <0.001 | |
Q4 | 4.725(2.453~6.997) | <0.001 |
变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
---|---|---|---|---|---|---|
TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
男性 | ||||||
TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
女性 | ||||||
TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
Table 6 ROC curve and subgroup analysis of different insulin resistance replacement indexes for the risk of HUA in T2DM patients
变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
---|---|---|---|---|---|---|
TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
男性 | ||||||
TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
女性 | ||||||
TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
变量 | HUA | NHUA | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 42 | 371 | 413 |
低 | 32 | 510 | 542 |
合计 | 74 | 881 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 46 | 430 | 476 |
低 | 28 | 451 | 479 |
合计 | 74 | 881 | 955 |
METS-IR指数 | |||
高 | 36 | 318 | 354 |
低 | 38 | 563 | 601 |
合计 | 74 | 881 | 955 |
Table 7 Nested case-control analysis of HUA occurrence
变量 | HUA | NHUA | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 42 | 371 | 413 |
低 | 32 | 510 | 542 |
合计 | 74 | 881 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 46 | 430 | 476 |
低 | 28 | 451 | 479 |
合计 | 74 | 881 | 955 |
METS-IR指数 | |||
高 | 36 | 318 | 354 |
低 | 38 | 563 | 601 |
合计 | 74 | 881 | 955 |
变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 221 | 192 | 413 |
低 | 145 | 397 | 542 |
合计 | 366 | 589 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 216 | 260 | 476 |
低 | 150 | 329 | 479 |
合计 | 366 | 589 | 955 |
METS-IR指数 | |||
高 | 186 | 168 | 354 |
低 | 180 | 421 | 601 |
合计 | 366 | 589 | 955 |
Table 8 Nested case-control study of blood glucose control in diabetic patients
变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 221 | 192 | 413 |
低 | 145 | 397 | 542 |
合计 | 366 | 589 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 216 | 260 | 476 |
低 | 150 | 329 | 479 |
合计 | 366 | 589 | 955 |
METS-IR指数 | |||
高 | 186 | 168 | 354 |
低 | 180 | 421 | 601 |
合计 | 366 | 589 | 955 |
[1] |
|
[2] |
中华医学会糖尿病学分会胰岛素抵抗学组(筹). 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志,2018,10(6):377-385. DOI:10.3760/cma.j.issn.1674-5809.2018.06.001.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
宋华隆,高鹰. 血尿酸水平与2型糖尿病发病风险的关联队列研究[J]. 中国全科医学,2023,26(15):1831-1839. DOI:10.12114/j.issn.1007-9572.2022.0785.
|
[11] |
段琼,张紫行,徐娟,等. 高尿酸血症与脂肪肝关联的前瞻性队列研究[J]. 中华疾病控制杂志,2022,26(12):1420-1425,1432. DOI:10.16462/j.cnki.zhjbkz.2022.12.010.
|
[12] |
|
[13] |
李歆旎,沈艳,金雪娟,等. 血尿酸与高血压的相关性研究[J]. 中国分子心脏病学杂志,2022,22(5):4897-4902. DOI:10.16563/j.cnki.1671-6272.2022.10.005.
|
[14] |
|
[15] |
|
[16] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志,2021,41(5):482-548. DOI:10.3760/cma.j.cn121383-20210825-08063.
|
[17] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13. DOI:10.3760/cma.j.issn.1000-6699.2020.01.001.
|
[18] | |
[19] |
中国疾病预防控制中心. 中国慢性病及其危险因素监测分析报告2004年[M]. 北京:中国协和医科大学出版社,2009.
|
[20] |
|
[21] | |
[22] |
|
[23] |
刘颖. 高尿酸对3T3-L1脂肪细胞IRS-1表达及其酪氨酸磷酸化水平的影响[D]. 长沙:中南大学,2013.
|
[24] |
董洋,赵心迪,曹慧霞,等. 2型糖尿病患者血尿酸水平与肾功能损伤的相关性[J]. 中华实用诊断与治疗杂志,2022,36(5):456-459. DOI:10.13507/j.issn.1674-3474.2022.05.005.
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] | |
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
杨媛,周光清,李宛霖,等. 不同肥胖指标在高尿酸血症风险预测中的应用价值比较研究[J]. 中国全科医学,2022,25(4):453-460. DOI:10.12114/j.issn.1007-9572.2021.00.281.
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] | |
[46] |
赵美茹,朱迪,刘淋,等. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报(医学版),2022,60(12):44-51. DOI:10.6040/j.issn.1671-7554.0.2022.0575.
|
[1] | ZHOU Jin, WANG Yan, WANG Hui, ZHANG Yinan, ZHI Xiaoxu, ZHANG Zhiyuan, XU Dejing, ZHOU Xin, ZHANG Liuliu. Construction of a Comprehensive Health Management Program for Elderly Postoperative Colorectal Cancer Patients [J]. Chinese General Practice, 2024, 27(21): 2600-2606. |
[2] | WANG Xiaoran, GUAN Xinyue, ZHANG Dan. Patient Delay and Associated Factors in Older Adults with Multimorbidity [J]. Chinese General Practice, 2024, 27(20): 2505-2511. |
[3] | XIE Kexin, DU Fang, ZHANG Dan. Influencing Factors for the Effectiveness of Family Doctor Contract Services for Elderly Patients with Multimorbidity in Communities [J]. Chinese General Practice, 2024, 27(20): 2512-2519. |
[4] | GUAN Xinyue, WANG Xiaoran, ZHANG Dan. Study of Medication Adherence and Its Influencing Factors among Elderly Patients with Multimorbidity [J]. Chinese General Practice, 2024, 27(20): 2520-2526. |
[5] | NIE Zuoting, CHEN Long, ZENG Kai, TAO Lu, YANG Rumei. Current Status of Research on Fall Risk Perception and Its Implications for Active Fall Prevention in Older Adults [J]. Chinese General Practice, 2024, 27(19): 2395-2400. |
[6] | GONG Yue, HUANG Yueqing, ZHANG Liang, ZHAO Chunhua, HUANG Min. External Validation of a 10-year Cardiovascular Risk Assessment Tool Based on an Older Population [J]. Chinese General Practice, 2024, 27(19): 2336-2343. |
[7] | JIANG Qixia, XIE Haoting, WANG Huajun, LI Xiuyun, ZHU Yuling, WANG Yaling, MIN Yan, WANG Ke. Effectiveness Analysis of Two Incontinence Care Plans Based on Guidelines for Elderly COVID-19 Patients with Incontinence [J]. Chinese General Practice, 2024, 27(18): 2212-2217. |
[8] | XU Yunjia, SHU Biyun, ZHENG Yongtao, CHEN Ting, LAI Fenhua, NI Mengjiao, LUO Xiulan, WU Hengjing. Risk Factors and Predictive Model of Long-term Bedridden Risk of Falls in Super-aged Population Based on Competing Risk Model Analysis [J]. Chinese General Practice, 2024, 27(18): 2192-2197. |
[9] | HUANG Ya, NI Wenji, ZHANG Rui, LI Dandan, ZHOU Ying, JIN Tao, ZHONG Yong. Correlation of Systemic Immune Inflammatory Index and Systemic Inflammatory Response Index with Microalbuminuria in Middle-aged and Elderly People Undergoing Health Examination [J]. Chinese General Practice, 2024, 27(18): 2186-2191. |
[10] | YIN Qiuguo, QIN Xintong, ZHANG Yidan, JIANG Peng, GUO Ping, JIA Xingtai, JIAN Liguo. Correlation between Insulin Resistance Metabolic Score and Poor Prognosis in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2024, 27(18): 2179-2185. |
[11] | ZHAO Ningxuan, JIANG Lin, HU Meijing, YAO Qiang, MAO Yineng, ZHU Cairong. Association between Cumulative Episodes of C-reactive Protein Elevations and Somatic/Non-somatic Depressive Symptoms among Chinese Middle-aged and Older Adults: Prospective Cohort Study [J]. Chinese General Practice, 2024, 27(17): 2070-2076. |
[12] | ZHANG Mengjie, ZHENG Xiao, LIAO Yanming, TIAN Feng, QIAN Juan, ZHOU Jiexing, ZHANG Chichen. Path Study of Social Networks in the Older Adults on Multimorbidity: the Mediating Effects of Physical Activity and Sleep [J]. Chinese General Practice, 2024, 27(17): 2130-2137. |
[13] | ZHENG Xiao, ZHANG Chichen, TIAN Feng, XUE Benli, LI Xinru, XIAO Shujuan, CHEN Yiming. Study on the Health Management Service Pathway for Multimorbidity of Middle-aged and Older Adults in the Community [J]. Chinese General Practice, 2024, 27(17): 2119-2123. |
[14] | LI Hang, LIU Suzhen, NI Yunxia. Sinicization Based on Community Health Intensity Rating Scale and Its Reliability and Validity Test in Elderly Patients [J]. Chinese General Practice, 2024, 27(16): 1950-1955. |
[15] | MA Jia, ZHANG Minjue, ZHANG Shaowei, YU Haiyan, CHEN Shen, Gulibaier MAMUTI, HONG Juan, LU Yuan. Community Management of Elderly Patients with Type 2 Diabetes Complicated with Mild Cognitive Impairment Related Factors [J]. Chinese General Practice, 2024, 27(16): 1984-1989. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||